Revenue rose 26.8% as Brukinsa and Tevimbra sales expanded, while the biotech lifted 2026 revenue and profit guidance after Sonrotoclax won U.S. FDA approval.
BeiGene reported first-half 2026 net profit attributable to parent shareholders of CNY 3.27 billion, or about $485.4 million, up 627.1% from a year earlier and already above its full-year 2025 total of CNY 1.42 billion, as product sales growth and tighter expense control widened earnings. Total operating revenue rose 26.8% to CNY 22.22 billion and core product revenue increased 25.6% to CNY 21.8 billion, while adjusted net profit climbed 127% to CNY 5.86 billion after excluding non-cash items. Growth was driven by BTK inhibitor (blood cancer target drug) Brukinsa, which generated CNY 16.13 billion in global sales including CNY 11.39 billion in the United States, alongside PD-1 inhibitor (immunotherapy checkpoint blocker) Tevimbra at CNY 2.98 billion and Amgen-partnered products at CNY 2.06 billion. The company also said Sonrotoclax, a BCL2 inhibitor (cell-death pathway blocker), received accelerated FDA (U.S. drug regulator) approval for relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies including a BTK inhibitor, and it raised 2026 guidance for revenue, operating cost expenses and adjusted operating cost expenses. Ahead of the results, BeiGene's A-shares rose 4.93% and 7.12% on August 4 and 5, lifting its A-share market capitalization to CNY 432.6 billion at the August 5 close and making it the second-largest pharmaceutical company on China's A-share market behind WuXi AppTec.